Parkinson’s Disease, Lithium and Stem Cells

Parkinson’s disease (PD) is a neurodegenerative disease characterized by loss of dopaminergic neurons in the substantia nigra. Current treatment only helps symptoms, and there is no effective treatment to delay or reverse PD. Scientists have regarded a number of genetic and environmental factors that may lead to developing PD. Lithium has been used for years in psychiatry as an effective mood stabilizer in manic depressive bipolar disorder (BD). This natural element is the most potent inhibitor of the enzyme glycogen synthetase kinase (GSK3) activity. Because of GSK3’s abundance in the body and over expression leading to PD, lithium has been postulated be used as a treatment for numerous neurodegenerative diseases and conditions where GSK3 is over expressed. Lithium has also been shown to be protective to cells against rotenone-induced PD. In contrast cellular based therapy, specifically the use of induced pluripotential stem cells (iPSCs), also pose a promising therapeutic modality for future use in order to more fully understanding the process of PD development.

• Publication year

  2019

• Venue

  Journal of Clinical and Laboratory Medicine

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.16966/2572-9578.126
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• [Parkinson's disease].

  2022cited by this paper
• Role of Autophagy in Parkinson's Disease.

  2019cited by this paper
• The Parkinson’s disease-linked Leucine-rich repeat kinase 2 (LRRK2) is required for insulin-stimulated translocation of GLUT4

  2019cited by this paper
• Mitochondrial dysfunction in neurodegenerative diseases and the potential countermeasure

  2019cited by this paper
• Cellular and Molecular Aspects of Parkinson Treatment: Future Therapeutic Perspectives

  2018cited by this paper
• COQ2 variants in Parkinson’s disease and multiple system atrophy

  2018cited by this paper
• Cerebrospinal fluid β‐glucocerebrosidase activity is reduced in parkinson's disease patients

  2017cited by this paper
• The MPTP Story

  2017cited by this paper
• The use of lithium for the treatment of bipolar disorder: Recommendations from clinical practice guidelines.

  2017influential reference
• Therapeutic potential of autophagy-enhancing agents in Parkinson’s disease

  2017cited by this paper
• A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci

  2017cited by this paper
• Alzheimer’s disease, dementia, and stem cell therapy

  2017cited by this paper
• Distinctive genomic signature of neural and intestinal organoids from familial Parkinson's disease patient‐derived induced pluripotent stem cells

  2017cited by this paper
• An updated review of Parkinson's disease genetics and clinicopathological correlations

  2017cited by this paper
• The effect of lithium on hematopoietic, mesenchymal and neural stem cells

  2016cited by this paper
• Overexpression of α-synuclein simultaneously increases glutamate NMDA receptor phosphorylation and reduces glucocerebrosidase activity.

  2016cited by this paper
• Initial treatment of Parkinson's disease in 2016: The 2000 consensus conference revisited.

  2016cited by this paper
• Induced pluripotent stem cells in Parkinson's disease: scientific and clinical challenges

  2016influential reference
• Parkinson disease (PARK) genes are somatically mutated in cutaneous melanoma

  2016influential reference
• Brain glucose metabolism changes in Parkinson's disease patients with CHCHD2 mutation based on (18)F-FDG PET imaging.

  2016cited by this paper
• A nonsense mutation in CHCHD2 in a patient with Parkinson disease

  2016cited by this paper
• Loss of Parkinson's disease-associated protein CHCHD2 affects mitochondrial crista structure and destabilizes cytochrome c

  2016cited by this paper
• The epidemiology of Parkinson's disease: risk factors and prevention.

  2016influential reference
• Midlife milk consumption and substantia nigra neuron density at death

  2016cited by this paper
• Cutaneous malignant melanoma and Parkinson disease: Common pathways?

  2016influential reference
• Lithium increases proliferation of hippocampal neural stem/progenitor cells and rescues irradiation-induced cell cycle arrest in vitro

  2015cited by this paper
• Potential application of lithium in Parkinson's and other neurodegenerative diseases

  2015cited by this paper
• Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.

  2015cited by this paper
• Physical activity and risk of Parkinson's disease in the Swedish National March Cohort.

  2015cited by this paper
• Review of lithium effects on immune cells

  2015cited by this paper
• F-box protein 7 mutations promote protein aggregation in mitochondria and inhibit mitophagy.

  2015cited by this paper
• Lithium enhanced cell proliferation and differentiation of mesenchymal stem cells to neural cells in rat spinal cord.

  2015cited by this paper
• Lithium protects dopaminergic cells from rotenone toxicity via autophagy enhancement

  2015cited by this paper
• Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases.

  2015influential reference
• CHCHD2 mutations in autosomal dominant late-onset Parkinson's disease: a genome-wide linkage and sequencing study.

  2015influential reference
• Systematic review of the risk of Parkinson's disease after mild traumatic brain injury: results of the International Collaboration on Mild Traumatic Brain Injury Prognosis.

  2014cited by this paper
• Concise Review: Evidence for CD34 as a Common Marker for Diverse Progenitors

  2014cited by this paper
• Human Finger‐Prick Induced Pluripotent Stem Cells Facilitate the Development of Stem Cell Banking

  2014cited by this paper
• Classics in chemical neuroscience: levodopa.

  2014cited by this paper
• Female reproductive factors, menopausal hormone use, and Parkinson's disease

  2014cited by this paper
• Long-term lithium treatment reduces glucose metabolism in the cerebellum and hippocampus of nondemented older adults: an [¹⁸F]FDG-PET study.

  2014cited by this paper
• Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease.

  2014cited by this paper
• Neuroprotective effects of lithium: implications for the treatment of Alzheimer's disease and related neurodegenerative disorders.

  2014cited by this paper
• Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease

  2014cited by this paper
• Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.

  2014cited by this paper
• Lithium stimulates human bone marrow derived mesenchymal stem cell proliferation through GSK‐3β‐dependent β‐catenin/Wnt pathway activation

  2014cited by this paper
• The spectrum of nonmotor symptoms in early Parkinson disease

  2013cited by this paper
• Exposure to estrogen and women's risk for Parkinson's disease: a prospective cohort study in Denmark.

  2013cited by this paper
• Death receptors and mitochondria: two prime triggers of neural apoptosis and differentiation.

  2013cited by this paper
• Genetic variability related to serum uric acid concentration and risk of Parkinson's disease

  2013cited by this paper
• Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression.

  2013cited by this paper
• Human Eukaryotic Initiation Factor 4G (eIF4G) Protein Binds to eIF3c, -d, and -e to Promote mRNA Recruitment to the Ribosome*

  2013cited by this paper
• Neuroprotective effects of chronic exposure of SH-SY5Y to low lithium concentration involve glycolysis stimulation, extracellular pyruvate accumulation and resistance to oxidative stress.

  2013cited by this paper
• Brain development in rodents and humans: Identifying benchmarks of maturation and vulnerability to injury across species.

  2013cited by this paper
• Wnt and lithium: a common destiny in the therapy of nervous system pathologies?

  2013cited by this paper
• Tau as a therapeutic target in neurodegenerative disease.

  2012cited by this paper
• Lithium reduced neural progenitor apoptosis in the hippocampus and ameliorated functional deficits after irradiation to the immature mouse brain.

  2012cited by this paper
• Toxin Models of Mitochondrial Dysfunction in Parkinson's Disease

  2012cited by this paper
• Premotor Parkinson's disease: Concepts and definitions

  2012cited by this paper
• Risk of Parkinson Disease Onset in Patients With Diabetes

  2012cited by this paper
• Identifying prodromal Parkinson's disease: Pre‐Motor disorders in Parkinson's disease

  2012cited by this paper
• Increased ratio of anti-apoptotic to pro-apoptotic Bcl2 gene-family members in lithium-responders one month after treatment initiation

  2012cited by this paper
• Head injury and Parkinson's disease: A population‐based study

  2012cited by this paper
• Lithium enhances remyelination of peripheral nerves

  2012cited by this paper
• Evidence of an association between the scavenger receptor class B member 2 gene and Parkinson's disease

  2012cited by this paper
• Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease

  2011cited by this paper
• Bioenergetics of neurons inhibit the translocation response of Parkin following rapid mitochondrial depolarization.

  2011cited by this paper
• Parkinsonism Associated with Glucocerebrosidase Mutation

  2011cited by this paper
• Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies.

  2011cited by this paper
• Diabetes and Risk of Parkinson’s Disease

  2011influential reference
• Diabetes and the Risk of Developing Parkinson’s Disease in Denmark

  2011cited by this paper
• Survival of Human Induced Pluripotent Stem Cell–Derived Midbrain Dopaminergic Neurons in the Brain of a Primate Model of Parkinson's Disease

  2011cited by this paper
• Lithium, an anti-psychotic drug, greatly enhances the generation of induced pluripotent stem cells

  2011cited by this paper
• Obesity, diabetes, and risk of Parkinson's disease

  2011cited by this paper
• Variation in the Uric Acid Transporter Gene SLC2A9 and Its Association with AAO of Parkinson’s Disease

  2011cited by this paper
• α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells.

  2011cited by this paper
• Translation initiator EIF4G1 mutations in familial Parkinson disease.

  2011cited by this paper
• Use of ibuprofen and risk of Parkinson disease

  2011cited by this paper
• Meta-analysis of the relationship between Parkinson disease and melanoma

  2011cited by this paper
• Epidemiology and etiology of Parkinson’s disease: a review of the evidence

  2011cited by this paper
• Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease

  2011cited by this paper
• LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress.

  2011cited by this paper
• Somatic coding mutations in human induced pluripotent stem cells

  2011cited by this paper
• Lithium Restores Neurogenesis in the Subventricular Zone of the Ts65Dn Mouse, a Model for Down Syndrome

  2010cited by this paper
• Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1ΔE9 mouse model of Alzheimer's disease

  2010cited by this paper
• Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson's disease.

  2010cited by this paper
• Persistent organochlorine pesticides in serum and risk of Parkinson disease

  2010cited by this paper
• The mechanism of eukaryotic translation initiation and principles of its regulation

  2010cited by this paper
• Serotonergic Neurons Mediate Dyskinesia Side Effects in Parkinson’s Patients with Neural Transplants

  2010cited by this paper
• Physical activities and future risk of Parkinson disease

  2010cited by this paper
• Protection of midbrain dopaminergic neurons by the end‐product of purine metabolism uric acid: potentiation by low‐level depolarization

  2009cited by this paper
• Deconstructing Stem Cell Tumorigenicity: A Roadmap to Safe Regenerative Medicine

  2009cited by this paper
• Regulation of translation initiation in eukaryotes: mechanisms and biological targets.

  2009cited by this paper
• Reproductive factors, exogenous estrogen use, and risk of Parkinson's disease

  2009cited by this paper
• The particular relationship between Parkinson’s disease and malignancy: a focus on skin cancers

  2009cited by this paper
• GOUT AND RISK OF PARKINSON DISEASE: A PROSPECTIVE STUDY

  2008cited by this paper
• Lithium treatment and risk of dementia.

  2008cited by this paper
• Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease

  2008cited by this paper
• Gout and the risk of Parkinson's disease: a cohort study.

  2008cited by this paper
• Inactivation of Glycogen Synthase Kinase 3 Promotes Axonal Growth and Recovery in the CNS

  2008cited by this paper

• No citing papers are available for this paper.